What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Breast Cancer | Research To Practice

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Breast Cancer

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Breast Cancer

Please note that slides and other materials provided are for review only and not to be repurposed or published.

Part 1: HER2-Positive Breast Cancer

Wednesday, December 7, 2022

View Full Slide Presentation

MODULE 1: Optimizing the Management of Localized HER2-Positive Breast Cancer — Dr Tolaney

MODULE 2: Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer — Dr Krop

MODULE 3: Management of HER2-Positive Breast Cancer with CNS Metastases — Dr Hamilton

MODULE 4: Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer — Dr Modi

MODULE 5: Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy — Dr Hurvitz

Part 2: ER-Positive Breast Cancer

Thursday, December 8, 2022

View Full Slide Presentation

MODULE 1: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Goetz

MODULE 2: Optimizing the Management of Localized ER-Positive Breast Cancer — Dr Kaklamani

MODULE 3: Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC) — Dr Kalinsky

MODULE 4: Recent Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer — Dr Bardia

MODULE 5: Novel Strategies Under Investigation for Patients with HR-Positive mBC — Dr Rugo